Loading
Anetumab ravtansine was the first antibody-drug conjugate tested in a randomised trial in mesothelioma, aimed at the mesothelin protein that nearly all mesotheliomas carry; it was no better than vinorelbine chemotherapy as second-line treatment, and is now being tried with pembrolizumab.
Bayer built anetumab ravtansine around mesothelin, a surface protein over-expressed in mesothelioma, ovarian, pancreatic and some lung cancers but scarce in normal tissue. In the 248-patient randomised phase 2 trial in relapsed, mesothelin-positive pleural mesothelioma after platinum and pemetrexed, median progression-free survival was 4.3 months with anetumab ravtansine against 4.5 months with vinorelbine (hazard ratio 1.22), with far less neutropenia but corneal and other toxicities, so development for mesothelioma as a single agent stopped. A National Cancer Institute phase 1/2 trial is testing it with pembrolizumab, and the drug remains the reference case for why mesothelin-directed conjugates have struggled: shed mesothelin in the blood soaks up antibody, expression is heterogeneous, and a tubulin payload adds little to a slow-growing tumour that already resists chemotherapy.
A fully human anti-mesothelin antibody linked through a disulfide linker to the maytansinoid tubulin inhibitor DM4; binding to mesothelin on the tumour cell surface internalises the conjugate and releases the payload. Connects to Mesothelin.
1.Anetumab ravtansine's antibody arm binds Mesothelin on the surface of the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
One trial page, one treatment page and one idea page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One treatment page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One treatment page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Query for this drug: (TITLE:"Anetumab ravtansine" OR ABSTRACT:"Anetumab ravtansine" OR TITLE:"BAY 94-9343" OR ABSTRACT:"BAY 94-9343") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Anetumab ravtansine, not a curated reading list.
Shares Mesothelioma and the tag owner-request.
Shares Pancreatic ductal adenocarcinoma and the tag owner-request.
Shares Pancreatic ductal adenocarcinoma and the tag owner-request.
Shares Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect, Antibody-drug conjugate (ADC).
Shares Mesothelin, Mesothelioma, Pancreatic ductal adenocarcinoma.
Shares Pleural mesothelioma, Mesothelioma, Pancreatic ductal adenocarcinoma.
Shares Pleural mesothelioma, Mesothelioma.
Shares Mesothelin, Antibody-drug conjugate (ADC), Ovarian cancer, Pancreatic ductal adenocarcinoma.